1. Peptides
  2. P8RI

P8RI (Synonyms: D-P8RI)

Cat. No.: HY-P3325 Purity: 98.19%
Handling Instructions

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

P8RI Chemical Structure

P8RI Chemical Structure

CAS No. : 2147724-76-1

Size Price Stock Quantity
5 mg USD 120 In-stock
Estimated Time of Arrival: December 31
10 mg USD 190 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway[1][2].

In Vitro

P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))[3]
Dosage: 2.5 mg/kg
Administration: Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
Result: Aneurysmal transformation was significantly reduced.
Molecular Weight

1016.24

Formula

C₅₁H₇₇N₁₃O₉

CAS No.
Sequence Shortening

KWPALFVR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (98.40 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9840 mL 4.9201 mL 9.8402 mL
5 mM 0.1968 mL 0.9840 mL 1.9680 mL
10 mM 0.0984 mL 0.4920 mL 0.9840 mL
*Please refer to the solubility information to select the appropriate solvent.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
P8RI
Cat. No.:
HY-P3325
Quantity:
MCE Japan Authorized Agent: